Correlation Between Karyopharm Therapeutics and Equillium

Can any of the company-specific risk be diversified away by investing in both Karyopharm Therapeutics and Equillium at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Karyopharm Therapeutics and Equillium into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Karyopharm Therapeutics and Equillium, you can compare the effects of market volatilities on Karyopharm Therapeutics and Equillium and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Karyopharm Therapeutics with a short position of Equillium. Check out your portfolio center. Please also check ongoing floating volatility patterns of Karyopharm Therapeutics and Equillium.

Diversification Opportunities for Karyopharm Therapeutics and Equillium

0.45

Correlation Coefficient

Karyopharm Therapeutics  Equillium

Very weak diversification

The 3 months correlation between Karyopharm and Equillium is 0.45. Overlapping area represents the amount of risk that can be diversified away by holding Karyopharm Therapeutics and Equillium in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Equillium and Karyopharm Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Karyopharm Therapeutics are associated (or correlated) with Equillium. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Equillium has no effect on the direction of Karyopharm Therapeutics i.e., Karyopharm Therapeutics and Equillium go up and down completely randomly.

Pair Corralation between Karyopharm Therapeutics and Equillium

Given the investment horizon of 90 days Karyopharm Therapeutics is expected to under-perform the Equillium. But the stock apears to be less risky and, when comparing its historical volatility, Karyopharm Therapeutics is 1.67 times less risky than Equillium. The stock trades about -0.65 of its potential returns per unit of risk. The Equillium is currently generating about -0.14 of returns per unit of risk over similar time horizon. If you would invest  74.00  in Equillium on September 25, 2024 and sell it today you would lose (9.42) from holding Equillium or give up 12.73% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Karyopharm Therapeutics  vs.  Equillium

Karyopharm Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Karyopharm Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest weak performance, the Stock's basic indicators remain strong and the recent confusion on Wall Street may also be a sign of long-lasting gains for the firm traders.

Equillium

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Equillium has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable basic indicators, Equillium is not utilizing all of its potentials. The current stock price agitation, may contribute to short-term losses for the retail investors.

Pair Trading with Karyopharm Therapeutics and Equillium

The main advantage of trading using opposite Karyopharm Therapeutics and Equillium positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Karyopharm Therapeutics position performs unexpectedly, Equillium can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Equillium will offset losses from the drop in Equillium's long position.

The idea behind Karyopharm Therapeutics and Equillium pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.